- The new formulation delivers anti-hepatitis B virus antibodies using a unique and sophisticated caprylate chromatography process
- Grifols has been a trusted global provider of hepatitis B immune globulin (HBIG) for over 45 years and continues to expand its leadership in disease treatment with immunoglobulin (IgG), building out its preeminent hyperimmune portfolio
- The manufacturing process provides for a significant reduction in procoagulant activity and IgG aggregates, and is the only HBIG to offer a neonatal syringe format specifically to protect infants born to hepatitis B surface antigen (HBsAg)-positive mothers
PR Newswire
BARCELONA, Spain, June 1, 2021